{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:24:45Z","timestamp":1783430685301,"version":"3.54.6"},"reference-count":28,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2012,4,16]]},"DOI":"10.4161\/hv.19229","type":"journal-article","created":{"date-parts":[[2012,5,2]],"date-time":"2012-05-02T21:15:53Z","timestamp":1335993353000},"page":"486-490","source":"Crossref","is-referenced-by-count":43,"title":["MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine"],"prefix":"10.1080","volume":"8","author":[{"given":"Manmohan","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Kazzaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mildred","family":"Ugozzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Baudner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn D.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillis","family":"Otten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek T.","family":"O\u2019Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,10,27]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: recent progress in adjuvant research","volume":"5","author":"Guy","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"R2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat Immunol"},{"key":"R3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2174\/1566524033479366","article-title":"Regulation of dendritic cell function through toll-like receptors","volume":"3","author":"Kaisho","year":"2003","journal-title":"Curr Mol Med"},{"key":"R4","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/eji.200324037","article-title":"Toll-like receptors: networking for success","volume":"33","author":"Underhill","year":"2003","journal-title":"Eur J Immunol"},{"key":"R5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1586\/14760584.2.2.219","article-title":"Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529","volume":"2","author":"Evans","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"R6","unstructured":"CERVARIX\u00ae Product Information Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted) GlaxoSmithKline Australia Pty Ltd. 2007."},{"key":"R7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/14760584.6.2.133","article-title":"New hepatitis B vaccine formulated with an improved adjuvant system","volume":"6","author":"Kundi","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"R8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Gar\u00e7on","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"R9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/14760584.6.4.559","article-title":"Improving vaccines by incorporating immunological coadjuvants","volume":"6","author":"Fraser","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"R10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0264-410X(02)00737-5","article-title":"Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice","volume":"21","author":"Przetak","year":"2003","journal-title":"Vaccine"},{"key":"R11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000069172","article-title":"A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis","volume":"49","author":"Banzhoff","year":"2003","journal-title":"Gerontology"},{"key":"R12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"O\u2019Hagan","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"R13","first-page":"211","article-title":"The Adjuvant MF59: A 10-Year Perspective","volume":"42","author":"Ott","year":"2000","journal-title":"Methods Mol Med"},{"key":"R14","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1016\/S0264-410X(99)00138-3","article-title":"Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly","volume":"17","author":"De Donato","year":"1999","journal-title":"Vaccine"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Podda A, Del Giudice G, O'Hagan D. MF59: a safe and potent adjuvant for human use. In V. Schijns, and D.T. O'Hagan (eds.); Immunopotentiators in modern vaccines. Academic Press, Oxford 2006:149-59.","DOI":"10.1016\/B978-012088403-2\/50010-1"},{"key":"R16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/14760584.2.2.197","article-title":"MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile","volume":"2","author":"Podda","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"R17","unstructured":"Podda A, Del Giudice G. MF59 adjuvant emulsion. 3rd ed. New York: Marcel Dekker, 2004."},{"key":"R18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1586\/14760584.6.5.773","article-title":"E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant","volume":"6","author":"Ishizaka","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"R19","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents","volume":"6","author":"Gill","year":"2010","journal-title":"Hum Vaccin"},{"key":"R21","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.4049\/jimmunol.176.10.6333","article-title":"T cell responses are better correlates of vaccine protection in the elderly","volume":"176","author":"McElhaney","year":"2006","journal-title":"J Immunol"},{"key":"R22","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"R23","unstructured":"www.gsk.com\/media\/flu\/flu-adjuvant.pdf (accessed 12\/17\/08)."},{"key":"R24","unstructured":"Ott G, Barchfeld G, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. Vaccine Design: The Subunit and Adjuvant Approach. New York, 1995."},{"key":"R25","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/S0264-410X(02)00272-4","article-title":"Synergistic adjuvant activity of immunostimulatory DNA and oil\/water emulsions for immunization with HIV p55 gag antigen","volume":"20","author":"O\u2019Hagan","year":"2002","journal-title":"Vaccine"},{"key":"R26","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s11095-009-9859-5","article-title":"MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020)","volume":"26","author":"Baudner","year":"2009","journal-title":"Pharm Res"},{"key":"R27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.vaccine.2007.11.054","article-title":"Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice","volume":"26","author":"Wack","year":"2008","journal-title":"Vaccine"},{"key":"R28","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.vaccine.2005.09.046","article-title":"A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens","volume":"24","author":"Singh","year":"2006","journal-title":"Vaccine"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/hv.19229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T05:05:19Z","timestamp":1561698319000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/hv.19229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,16]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,10,27]]},"published-print":{"date-parts":[[2012,4,16]]}},"alternative-id":["10.4161\/hv.19229"],"URL":"https:\/\/doi.org\/10.4161\/hv.19229","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,16]]}}}